Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||ABL1 R332W|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ABL1 R332W||lung adenocarcinoma||sensitive||Dasatinib||Preclinical||Actionable||In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) in culture (PMID: 26758680).||26758680|
|ABL1 R332W||lung adenocarcinoma||sensitive||Imatinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Gleevec (imatinib) inhibited growth of a lung adenocarcinoma cell line harboring ABL1 R332W (also reported as R351W) in culture, and inhibited tumor growth in xenograft models (PMID: 26758680).||26758680|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|